All In Biotech

Drug Trial Radar · NCT06440967

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women With Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 982 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

982

Actual

Start

Jul 31, 2024

Primary completion

Jun 25, 2026

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but cannot be given to women on hormone therapy for breast cancer. Fezolinetant, an alternative to HRT, treats hot flashes for women in menopause. As hot flashes happen in the same way for women on hormone therapy for breast cancer, fezolinetant could help these women. In this study, women on hormone therapy for breast cancer who have moderate to severe hot flashes will take part. They will either take fezolinetant or a placebo to treat their hot flashes. The placebo looks like fezolinetant but doesn't have any medicine in it. The main aim of this study is to confirm if women who take fezolinetant have fewer hot flashes that are less severe compared to women who take the placebo. Women 18 years or older seeking treatment for hot flashes. They can take part in the study if they have an average of 7 or more moderate to severe hot flashes each day. They are having hormone therapy for breast cancer from stage 0 (cancer cells that have not spread to nearby tissue) up to stage 3+ (the cancer has spread from the breast to the lymph nodes near the breast or the chest wall). The women will be assigned 1 of 2 study treatments (fezolinetant or placebo) by chance alone. Treatment will be double-blinded. That means that the women in the study and the study doctors will not know who takes which of the study treatments (fezolinetant or placebo). Women who take part in the study will take 1 tablet every day for 52 weeks (1 year). Each woman will be given an electronic handheld device with an app to track their hot flashes on a daily basis. Some women may be able to use the app on their own smartphone. They will also use another device to answer questions about how hot flashes affect their daily life. During the study, the women will visit their study clinic about every 4 weeks for a health check. The last clinic visit will be 3 weeks after the women take their last tablet of study treatment (fezolinetant or placebo). After this visit the women will be called twice to check their health. The women will be in the study for about 2 years.

Conditions

  • Hot Flashes

Interventions

  • FezolinetantDrug

    oral

  • PlaceboDrug

    oral

  • TamoxifenDrug

    oral

  • Aromatase inhibitorDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from Baseline to Week 4 in the frequency of moderate to severe VMSTime frame: Baseline to Week 4
  2. Mean change from Baseline to Week 12 in the frequency of moderate to severe VMSTime frame: Baseline to Week 12
  3. Mean change from Baseline to Week 4 in the severity of moderate to severe VMSTime frame: Baseline to Week 4
  4. Mean change from Baseline to Week 12 in the severity of moderate to severe VMSTime frame: Baseline to Week 12

Locations

110 sites in 11 countries. Site status is shown where the registry gives one.

  • Site CA15007

    Trois-Rivières, Canada

  • Site CA15019

    Sarnia, Ontario, Canada

  • Site CA15016

    Sault Ste. Marie, Ontario, Canada

  • Site CA15002

    Montreal, Quebec, Canada

  • Site CA15001

    Québec, Quebec, Canada

  • Site CA15004

    Québec, Quebec, Canada

  • Site CA15003

    Sherbrooke, Quebec, Canada

  • Site CA15020

    Victoriaville, Quebec, Canada

  • Site CZ42006

    České Budějovice, Czechia

  • Site CZ42003

    Hořovice, Czechia

  • Site CZ42002

    Hradec Králové, Czechia

  • Site CZ42011

    Nový Jičín, Czechia

  • Site CZ42001

    Olomouc, Czechia

  • Site CZ42005

    Prague, Czechia

  • Site CZ42008

    Prague, Czechia

  • Site CZ42013

    Prague, Czechia

  • Site CZ42004

    Tábor, Czechia

  • Site CZ42007

    Vodňany, Czechia

  • Site CZ42009

    Vsetín, Czechia

  • Site DK45007

    Aalborg, Denmark

  • Site DE45003

    Esbjerg, Denmark

  • Site DK45009

    Hillerød, Denmark

  • Site DK45002

    Næstved, Denmark

  • Site DE45008

    Sønderborg, Denmark

  • Site FR33003

    Angers, France

  • Site FR33001

    Bayonne, France

  • Site FR33005

    Bordeaux, France

  • Site FR33018

    Bordeaux, France

  • Site FR33017

    Caen, France

  • Site FR33016

    Dijon, France

  • Site FR33013

    Le Mans, France

  • Site FR33007

    Lille, France

  • Site FR33012

    Lyon, France

  • Site FR33008

    Montpellier, France

  • Site FR33002

    Saint-Herblain, France

  • Site DE49001

    Bottrop, Germany

  • Site GR49013

    Dresden, Germany

  • Site DE49009

    Leipzig, Germany

  • Site DE49007

    Mönchengladbach, Germany

  • Site DE49010

    München, Germany

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.